메뉴 건너뛰기




Volumn 143, Issue 1, 2014, Pages 159-169

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

(18)  Huober, J a,b,r   Cole, B F c,d   Rabaglio, M e,f   Giobbie Hurder, A d   Wu, J c   Ejlertsen, B g   Bonnefoi, H h   Forbes, J F i   Neven, P j   Lang I k   Smith, I l   Wardley, A m   Price, K N d,n   Goldhirsch, A o   Coates, A S e,p   Colleoni, M o   Gelber, R D d,n,q   Thurlimann B a,b  


Author keywords

Aromatase inhibitor; Breast cancer; Endocrine therapy; Side effects

Indexed keywords

LETROZOLE; TAMOXIFEN;

EID: 84892781922     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2792-7     Document Type: Article
Times cited : (32)

References (36)
  • 1
    • 84857605169 scopus 로고    scopus 로고
    • Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 1:STN:280:DC%2BC3Mjpt1yltg%3D%3D 21802721 10.1016/S0140-6736(11)60993-8
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771-784
    • (2011) Lancet , vol.378 , pp. 771-784
    • Davies, C.1    Godwin, J.2    Gray, R.3
  • 2
    • 81255157751 scopus 로고    scopus 로고
    • Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8·1 years median follow-up
    • 1:CAS:528:DC%2BC3MXhsVSktrnN 3235950 22018631 10.1016/S1470-2045(11) 70270-4
    • Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 12:1101-1108
    • (2011) Lancet Oncol , vol.12 , pp. 1101-1108
    • Regan, M.M.1    Neven, P.2    Giobbie-Hurder, A.3
  • 3
    • 78649603622 scopus 로고    scopus 로고
    • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer. 10-year analysis of the ATAC trial
    • 1:CAS:528:DC%2BC3cXhsVyhsLnF 21087898 10.1016/S1470-2045(10)70257-6
    • Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer. 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141
    • (2010) Lancet Oncol , vol.11 , pp. 1135-1141
    • Cuzick, J.1    Sestak, I.2    Baum, M.3
  • 4
    • 10744223655 scopus 로고    scopus 로고
    • A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    • 1:CAS:528:DC%2BD2cXitV2qtbc%3D 15014181 10.1056/NEJMoa040331
    • Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
    • (2004) N Engl J Med , vol.350 , pp. 1081-1092
    • Coombes, R.C.1    Hall, E.2    Gibson, L.J.3
  • 5
    • 0034749898 scopus 로고    scopus 로고
    • Minireview: Aromatase and the regulation of estrogen biosynthesis-some new perspectives
    • 1:CAS:528:DC%2BD3MXnslGqt7g%3D 11606422 10.1210/en.142.11.4589
    • Simpson ER, Davis SR (2001) Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 142:4589-4594
    • (2001) Endocrinology , vol.142 , pp. 4589-4594
    • Simpson, E.R.1    Davis, S.R.2
  • 6
    • 79960491885 scopus 로고    scopus 로고
    • Aromatase inhibitor-associated bone and musculoskeletal effects: New evidence defining etiology and strategies for management
    • 1:CAS:528:DC%2BC3MXksVyjsrY%3D 3219175 21457526 10.1186/bcr2818
    • Gaillard S, Stearns V (2011) Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 13:205
    • (2011) Breast Cancer Res , vol.13 , pp. 205
    • Gaillard, S.1    Stearns, V.2
  • 7
    • 0346602691 scopus 로고    scopus 로고
    • Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
    • 1:CAS:528:DC%2BD3sXpvVelsbc%3D 14652237 10.1093/jnci/djg108
    • Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764
    • (2003) J Natl Cancer Inst , vol.95 , pp. 1758-1764
    • Stearns, V.1    Johnson, M.D.2    Rae, J.M.3
  • 8
    • 19944434201 scopus 로고    scopus 로고
    • CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    • 1:CAS:528:DC%2BD2MXisVaqsw%3D%3D 15632378 10.1093/jnci/dji005
    • Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39
    • (2005) J Natl Cancer Inst , vol.97 , pp. 30-39
    • Jin, Y.1    Desta, Z.2    Stearns, V.3
  • 9
    • 33745347897 scopus 로고    scopus 로고
    • Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment
    • 1:CAS:528:DC%2BD28Xms1enu7k%3D 16815318 10.1016/j.clpt.2006.03.013
    • Borges S, Desta Z, Li L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74
    • (2006) Clin Pharmacol Ther , vol.80 , pp. 61-74
    • Borges, S.1    Desta, Z.2    Li, L.3
  • 10
    • 80052663463 scopus 로고    scopus 로고
    • Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis
    • 1:CAS:528:DC%2BC3MXhtFKisbjJ 21743022 10.1093/jnci/djr242
    • Amir E, Seruga B, Niraula S et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299-1309
    • (2011) J Natl Cancer Inst , vol.103 , pp. 1299-1309
    • Amir, E.1    Seruga, B.2    Niraula, S.3
  • 11
    • 84860618475 scopus 로고    scopus 로고
    • Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer
    • 1:CAS:528:DC%2BC38Xmt1Sgs7g%3D 22331951 10.1200/JCO.2011.38.0261
    • Henry NL, Azzouz F, Desta Z et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936-942
    • (2012) J Clin Oncol , vol.30 , pp. 936-942
    • Henry, N.L.1    Azzouz, F.2    Desta, Z.3
  • 12
    • 24644513947 scopus 로고    scopus 로고
    • Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining?
    • 16051966 10.1200/JCO.2005.00.6916
    • Peréz-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235-5246
    • (2005) J Clin Oncol , vol.23 , pp. 5235-5246
    • Peréz-Soler, R.1    Saltz, L.2
  • 13
    • 78649537524 scopus 로고    scopus 로고
    • Biomarkers to predict the clinical efficacy of bevacizumab in cancer
    • 1:CAS:528:DC%2BC3cXhsVyhsLbP 21126687 10.1016/S1470-2045(10)70232-1
    • Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172-1183
    • (2010) Lancet Oncol , vol.11 , pp. 1172-1183
    • Jubb, A.M.1    Harris, A.L.2
  • 15
    • 0035884457 scopus 로고    scopus 로고
    • Exact inference for categorical data: Recent advances and continuing controversies
    • 1:STN:280:DC%2BD3MvnvFGnsg%3D%3D 11523078 10.1002/sim.738
    • Agresti A (2001) Exact inference for categorical data: recent advances and continuing controversies. Stat Med 20:2709-2722
    • (2001) Stat Med , vol.20 , pp. 2709-2722
    • Agresti, A.1
  • 16
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observation
    • 10.1080/01621459.1958.10501452
    • Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 17
    • 0013886333 scopus 로고
    • Evaluation of survival data and two new rank order statistics arising in its consideration
    • 1:STN:280:DyaF287ht1Wgug%3D%3D
    • Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports 50:163-170
    • (1966) Cancer Chemotherapy Reports , vol.50 , pp. 163-170
    • Mantel, N.1
  • 18
    • 0000120995 scopus 로고
    • A class of k-sample tests for comparing the cumulative incidence of a competing risk
    • 10.1214/aos/1176350951
    • Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154
    • (1988) Ann Stat , vol.16 , pp. 1141-1154
    • Gray, R.J.1
  • 19
    • 0000336139 scopus 로고
    • Regression models and life tables
    • Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187-220
    • (1972) J R Stat Soc B , vol.34 , pp. 187-220
    • Cox, D.R.1
  • 20
    • 1542532754 scopus 로고    scopus 로고
    • A proportional hazards model for the subdistribution of a competing risk
    • 10.1080/01621459.1999.10474144
    • Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509
    • (1999) J Am Stat Assoc , vol.94 , pp. 496-509
    • Fine, J.P.1    Gray, R.J.2
  • 22
    • 56449112123 scopus 로고    scopus 로고
    • Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial
    • 1:CAS:528:DC%2BD1cXhsVWrsL7J 18976959 10.1016/S1470-2045(08)70259-6
    • Cuzick J, Sestak I, Cella D et al (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9:1143-1148
    • (2008) Lancet Oncol , vol.9 , pp. 1143-1148
    • Cuzick, J.1    Sestak, I.2    Cella, D.3
  • 23
    • 78751647876 scopus 로고    scopus 로고
    • Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial
    • 21247627 10.1016/S0140-6736(10)62312-4
    • van de Velde CJ, Rea D, Seynaeve C et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321-331
    • (2011) Lancet , vol.377 , pp. 321-331
    • Van De Velde, C.J.1    Rea, D.2    Seynaeve, C.3
  • 24
    • 84867130491 scopus 로고    scopus 로고
    • Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: A retrospective analysis of the German cohort of TEAM
    • 1:STN:280:DC%2BC38rhsVynsg%3D%3D 22467902 10.1093/annonc/mds055
    • Hadji P, Kieback DG, Tams J et al (2012) Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. Ann Oncol 23:2566-2572
    • (2012) Ann Oncol , vol.23 , pp. 2566-2572
    • Hadji, P.1    Kieback, D.G.2    Tams, J.3
  • 25
    • 84883047727 scopus 로고    scopus 로고
    • Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An international tamoxifen exemestane adjuvant multinational trial analysis
    • 1:CAS:528:DC%2BC3sXhtVGiu73P 23610112 10.1200/JCO.2012.45.3068
    • Fontein DB, Seynaeve C, Hadji P et al (2013) Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 31:2257-2264
    • (2013) J Clin Oncol , vol.31 , pp. 2257-2264
    • Fontein, D.B.1    Seynaeve, C.2    Hadji, P.3
  • 26
    • 80755126820 scopus 로고    scopus 로고
    • Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial
    • 10.1200/JCO.2010.34.4614
    • Stearns V, Chapman JW, Ma CX et al (2011) Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. J Clin Oncol 29(31):4189-4198
    • (2011) J Clin Oncol , vol.29 , Issue.31 , pp. 4189-4198
    • Stearns, V.1    Chapman, J.W.2    Ma, C.X.3
  • 27
    • 84878232154 scopus 로고    scopus 로고
    • Treatment emergent symptoms and the risk of breast cancer recurrence in the NCIC CTG MA 27. Adjuvant aromatase inhibitor trial
    • Stearns V, Chapman JA, Ma C et al (2009) Treatment emergent symptoms and the risk of breast cancer recurrence in the NCIC CTG MA 27. Adjuvant aromatase inhibitor trial. Cancer Res 69(20):1489-1498
    • (2009) Cancer Res , vol.69 , Issue.20 , pp. 1489-1498
    • Stearns, V.1    Chapman, J.A.2    Ma, C.3
  • 28
    • 84859159091 scopus 로고    scopus 로고
    • Carpal tunnel symptoms and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: A retrospective analysis of the Intergroup Exemestane Study
    • 22265698 10.1016/S1470-2045(11)70328-X
    • Mieog JSD, Morden JP, Bliss JM et al (2012) Carpal tunnel symptoms and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol 13:420-432
    • (2012) Lancet Oncol , vol.13 , pp. 420-432
    • Mieog, J.S.D.1    Morden, J.P.2    Bliss, J.M.3
  • 29
    • 82455175236 scopus 로고    scopus 로고
    • Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer
    • 1:CAS:528:DC%2BC3MXhsV2hsr3O 21442439 10.1007/s00280-011-1615-y
    • Park IH, Lee YS, Lee KS et al (2011) Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol 68:1263-1271
    • (2011) Cancer Chemother Pharmacol , vol.68 , pp. 1263-1271
    • Park, I.H.1    Lee, Y.S.2    Lee, K.S.3
  • 30
    • 84860389786 scopus 로고    scopus 로고
    • Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors
    • 1:CAS:528:DC%2BC3MXhvVKltLc%3D 3109575 21251330 10.1186/bcr2813
    • Mao JJ, Su HI, Feng R et al (2011) Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 13:R8
    • (2011) Breast Cancer Res , vol.13 , pp. 8
    • Mao, J.J.1    Su, H.I.2    Feng, R.3
  • 31
    • 78149250018 scopus 로고    scopus 로고
    • Genome-wide association and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors
    • 1:CAS:528:DC%2BC3cXhsF2rtLzO 20876420 10.1200/JCO.2010.28.5064
    • Ingle JN, Schaid DJ, Goss PE (2010) Genome-wide association and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28:4674-4682
    • (2010) J Clin Oncol , vol.28 , pp. 4674-4682
    • Ingle, J.N.1    Schaid, D.J.2    Goss, P.E.3
  • 32
    • 41149083559 scopus 로고    scopus 로고
    • Tamoxifen, hot flashes and breast cancer recurrence
    • 1:CAS:528:DC%2BD1cXjsFGisbw%3D 10.1007/s10549-007-9612-x
    • Mortimer JE, Flatt SW, Parker BA et al (2008) Tamoxifen, hot flashes and breast cancer recurrence. Breast Cancer Res and Treat 108:421-426
    • (2008) Breast Cancer Res and Treat , vol.108 , pp. 421-426
    • Mortimer, J.E.1    Flatt, S.W.2    Parker, B.A.3
  • 33
    • 84859093970 scopus 로고    scopus 로고
    • CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial
    • 1:CAS:528:DC%2BC38Xksl2rsbo%3D 22395644 10.1093/jnci/djs125
    • Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104:441-451
    • (2012) J Natl Cancer Inst , vol.104 , pp. 441-451
    • Regan, M.M.1    Leyland-Jones, B.2    Bouzyk, M.3
  • 34
    • 84859054082 scopus 로고    scopus 로고
    • CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients
    • 1:CAS:528:DC%2BC38Xksl2rsb8%3D 22395643 10.1093/jnci/djs126
    • Rae JM, Drury S, Hayes DF et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452-460
    • (2012) J Natl Cancer Inst , vol.104 , pp. 452-460
    • Rae, J.M.1    Drury, S.2    Hayes, D.F.3
  • 35
    • 71549140399 scopus 로고    scopus 로고
    • Adverse symptom event reporting by patients versus clinicians: Relationships with clinical outcomes
    • 19920223 10.1093/jnci/djp386
    • Basch E, Jia X, Heller G et al (2009) Adverse symptom event reporting by patients versus clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624-1632
    • (2009) J Natl Cancer Inst , vol.101 , pp. 1624-1632
    • Basch, E.1    Jia, X.2    Heller, G.3
  • 36
    • 33750305266 scopus 로고    scopus 로고
    • Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study
    • 17081915 10.1016/S1470-2045(06)70910-X
    • Basch E, Iasonos A, McDonough T et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903-909
    • (2006) Lancet Oncol , vol.7 , pp. 903-909
    • Basch, E.1    Iasonos, A.2    McDonough, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.